KPRX — Kiora Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $10.09m
- -$16.70m
- $16.02m
- 46
- 99
- 28
- 59
Annual cashflow statement for Kiora Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -8.09 | -13.8 | -13.6 | -12.5 | 3.59 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 1.05 | 4.28 | 2.56 | 4.64 | 1.57 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.321 | -1.04 | 0.669 | -1.82 | 3.67 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -7.32 | -10.7 | -10.4 | -9.56 | 8.56 |
| Capital Expenditures | -0.02 | -0.064 | 0 | — | -0.006 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -0.224 | -0.093 | 0.006 | 0 | -22.7 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.244 | -0.157 | 0.006 | 0 | -22.7 |
| Financing Cash Flow Items | -0.499 | -1 | -0.016 | -0.053 | 13.8 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 5 | 17.6 | 8.62 | 5.97 | 15.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.59 | 6.67 | -1.89 | -3.55 | 1.34 |